Thu, Oct 31, 2024
USFDA's VAI classification boosts Cipla’s outlook for niche drug launches, including Abraxane generic
More >
'Diwali Offer' Stocks by Anil Singhvi: Stock markets have been very volatile in last one month. Benchmark equity indices Sensex and Nifty fell in early trade even Thursday i.e. October 31, 2024. Amid this, investors are looking for stocks that can offer good return in long term.
Tue, Oct 29, 2024
Zee Business forecasts indicate a three percent year-on-year revenue increase, with Cipla’s Q2 revenue expected at Rs 6,892 crore, up from Rs 6,678 crore in the same quarter last year
Wed, Dec 29, 2021
The rise of the Covid-19 variant Omicron has once again brought pharma shares in focus.
Mon, Dec 27, 2021
Spotlight was on Nifty Pharma as the index was the top gainer around this time. It was trading at 13,710.80 and near its intraday high, up 1.6 per cent from the Friday closing level
Sun, Dec 19, 2021
Drug major Cipla on Sunday said it has received approval from the US health regulator to market the Lanreotide injection, used for the treatment of acromegaly and gastroenteropancreatic neuroendocrine tumors, in the American market
Fri, Nov 26, 2021
As the bears grip the market during Friday’s session, metal, auto, and pharma stocks witnessed a maximum buzz. In this regard, JSW Steel, Tata Motors, Hindalco slipped most, while Cipla and Dr Reddy’s were the top gainers in the otherwise negative market.
Tue, Oct 26, 2021
Drug major Cipla on Tuesday said its consolidated profit after tax (PAT) rose by 7 per cent to Rs 711 crore for the second quarter ending September, aided by strong performance in the domestic as well as international markets.
Thu, Sep 30, 2021
Cardiovascular disease (CVD) is the leading cause of mortality and accounts for one-third of global deaths. Cardiac has displaced anti-infectives as the leading therapy in the India Pharma Market (IPM).
Wed, Sep 29, 2021
Sun Pharmaceuticals – The shares of Sun Pharma today ended at Rs 790.50 on Tuesday, up 3.6 per cent from the Monday closing price. He puts target price at Rs 850-Rs 880 with a stop loss at Rs 755. The stock has seen some correction after attaining a 52-week high of Rs 804.35 on 3 August
Sun, Sep 19, 2021
Sandeep Jain recommends Cipla as an intraday pick on Monday. This is from the F&O segment. This stock was recommended at Rs 954. He puts the target price at Rs 965 while the stop loss at Rs 947
Thu, Aug 12, 2021
Drug firm Cipla has received approval from the US health regulator to market Difluprednate Ophthalmic Emulsion in the American market.
Wed, Jun 30, 2021
As Drugs Controller General of India (DCGI) allowed Cipla to import Moderna’s Covid-19 vaccine, the shares of the pharma major hit a new 52-week high of Rs 997.20 after rallying almost two per cent on the BSE intraday trade on Wednesday. The stock has surged around four per cent since Monday.
Tue, Jun 29, 2021
Moderna's vaccine will be the fourth COVID-19 jab to be available in India after Covishield, Covaxin and Sputnik.
Stock Markets ended in the red on Tuesday. The BSE Sensex closed at 52,567.30 today, down by over 168 points or 0.3 per cent. Meanwhile, the broader Market NSE Nifty 50 ended at 15,748.45, down by 66 points or 0.4 per cent
Sun, Jun 20, 2021
The stock markets on Friday traded with high volatility. The markets opened without much noise and then fell steeply. Nifty 50 had a free fall and touching around levels of 15,450 on the intraday basis which was a crucial level. The previous lifetime was 15,431 and the markets took a support at this level. Market Analyst Sandeep Jain said that last trading session of the week was extremely action packed.
Thu, May 20, 2021
Cipla share price: Sharekhan expects Cipla’s topline and PAT to report a CAGR of 11.9% and 23.8%, respectively, over FY2021-FY2023E.
Kedar Upadhye, Global Chief Finance Officer, Cipla, talks about March quarter numbers, market share of Albuetrol in the US market, the deal with Eli Lilly for the drug Baricitinib, production of Remedisvir black fungus drug and guidance for FY22 among others during a candid chat with Swati Khandelwal, Zee Business.
Wed, May 19, 2021
Kedar Upadhye, Global Chief Finance Officer, Cipla, talks about March quarter numbers, market share of Albuetrol in the US market, the deal with Eli Lilly for the drug Baricitinib, production of Remedisvir black fungus drug and guidance for FY22 among others during a candid chat with Zee Business Executive Swati Khandelwal
Cipla share price: Sharekhan says that Cipla Limited reported strong numbers for Q4FY2021 yoy, though it missed estimates. Results reflect a one time adjustments in gross margins to the tune of 200 bps on account of inventory adjustment for gAlbuterol and charge on material cost inventories. Revenue, at Rs 4606.5 cr, grew by 5% yoy, driven by a 17% rise in US revenues; sales from emerging markets and India grew by 4% yoy each
Mon, May 17, 2021
Amid the fourth quarter results being sharply below estimates, the brokerage firms post mixed sentiments towards the pharma major Cipla. However, the company reported a 68 per cent jump in the consolidated net profit in the March-ended quarter of the financial year 2020-2021.
Fri, May 14, 2021
Drug major Cipla on Friday today posted 73 per cent rise in consolidated net profit at Rs 412 crore for the fourth quarter ended March 31, 2021 on the back of robust sales across markets. The Mumbai-based firm had reported a net profit of Rs 238 crore in January-March 2019-20
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
